Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

[1]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[2]  K. Sagoe,et al.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients , 2009, AIDS.

[3]  Huldrych F. Günthard,et al.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.

[4]  L. Morris,et al.  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[5]  G. Maartens,et al.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. , 2008, JAMA.

[6]  T. Harrer,et al.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.

[7]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[8]  S. Matsushita,et al.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M Schwab,et al.  Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.

[10]  P. Binkley,et al.  Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues , 2006, Pharmacogenetics and genomics.

[11]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[12]  M. Ingelman-Sundberg,et al.  Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz , 2006, Pharmacogenetics and genomics.

[13]  Toshikazu Saito.  [Alcohol-related disorders]. , 2006, Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica.

[14]  M. Ziats,et al.  Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea , 2006, European Journal of Clinical Pharmacology.

[15]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[16]  K. Tashima,et al.  Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals , 2005, Annals of Internal Medicine.

[17]  L. López-Cortés,et al.  Therapeutic Drug Monitoring of Efavirenz: Trough Levels Cannot Be Estimated on the Basis of Earlier Plasma Determinations , 2005, Journal of acquired immune deficiency syndromes.

[18]  B. Clotet,et al.  Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence , 2005, Journal of acquired immune deficiency syndromes.

[19]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[20]  A. Sönnerborg,et al.  Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.

[21]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[22]  S. Hammer,et al.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. , 2004, JAMA.

[23]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  C. Flexner.  Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[25]  Jacques Fellay,et al.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.

[26]  H. Klinker,et al.  Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. , 2002, European journal of medical research.

[27]  M. Robinowitz,et al.  Preliminary evaluation of quantitative clinical laboratory methods; Approved guideline - 2. ed. NCCLS document EP 10-A2 , 2002 .

[28]  A. de Alarcón,et al.  Efavirenz plasma concentrations and efficiency. , 2001, AIDS.

[29]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[30]  Patrick F. Smith,et al.  Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors , 2001, Clinical pharmacokinetics.

[31]  E. Lonn,et al.  Provider-initiated HIV testing in rural Haiti: low rate of missed opportunities for diagnosis of HIV in a primary care clinic , 2007, AIDS Research and Therapy.

[32]  T. Aoyama,et al.  cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. , 1989, Biochemistry.